Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer
Altan M, Soto F, Xu T, Wilson N, Franco-Vega M, Clavijo C, Shannon V, Faiz S, Gandhi S, Lin S, Lopez P, Zhong L, Akhmedzhanov F, Godoy M, Shroff G, Wu J, Khawaja F, Kim S, Naing A, Heymach J, Daniel-Macdougall C, Liao Z, Sheshadri A. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clinical Oncology 2023, 35: 630-639. PMID: 37507279, DOI: 10.1016/j.clon.2023.07.003.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Non-Small-Cell LungChemoradiotherapyHumansImmune Checkpoint InhibitorsLung NeoplasmsPneumoniaRadiation PneumonitisRetrospective StudiesConceptsLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerImmune checkpoint inhibitionLA-NSCLCCell lung cancerInterstitial lung diseaseCheckpoint inhibitionLung cancerLung diseaseRisk factorsMultivariate Cox proportional hazards modelAssociated with higher all-cause mortalityLA-NSCLC patientsMean radiation doseHazards modelMultivariable cause-specific hazards modelRetrospective chart reviewCox proportional hazards modelsAll-cause mortalityProportional hazards modelCombined chemoradiationConcurrent chemoradiationMedian ageCause-specific hazard model